Congenital hypothyroidism can result from mutations in human iodotyrosine deiodinase (hIYD), which catalyzes the deiodination of iodotyrosines (I-Tyr), a key step in thyroid hormone synthesis. Three homozygous mutations (R101W, F105-I106L, and I116T) are known causes of hypothyroidism. This computational study reveals that of the two loop I mutations in the flavin-binding domain (R101W and F105-I106L), F105-I106L has a stronger effect, causing greater structural distortion and weaker packing at the dimerization interface. These mutations reduce the binding energy of flavin and I-Tyr, compared to the wild type, due to a complete loss of R101 crown-like phosphate hydrogen bond in R101W and a partial loss of R101 and R279 hydrogen bonds in F105-I106L. In contrast, the distal I116T mutation has a marginal structural effect, but it alters the solvent-accessible surface area, van der Waals packing, and side-chain flexibility, which may explain its delayed clinical onset. Although the I116T mutation is far from the active site, it strengthens flavin and substrate binding via long-range effects. Protein-folding analysis via the Wako-Saitô-Muñoz-Eaton model shows that the wt-hIYD and R101W fold through the C-terminal region, while F105-I106L and I116T alter the folding pathway. Mutation-specific disruptions can impair electron transfer by altering I-Tyr alignment and flavin ring planarity. These findings reveal how hIYD mutations cause structural, energetic, and catalytic defects linked to hypothyroidism.
Karmakar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: